Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Takeda Pharmaceutical : Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal

share with twitter share with LinkedIn share with facebook
share via e-mail
06/28/2020 | 11:34pm EDT
FILE PHOTO: The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo

Takeda Pharmaceutical Co Ltd said on Monday it anticipates an operating loss of about $200 million related to Novartis AG's decision to withdraw a marketing application for the dry-eye drug Xiidra.

The drug was one of the products Takeda obtained through its acquisition of Shire Plc in January 2019. In July 2019, Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.

Swiss drugmaker Novartis last week withdrew an application for European approval of Xiidra after regulators concluded its effectiveness had not been demonstrated.

(Reporting by Rocky Swift; Editing by Tom Hogue)

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG 1.88% 83.03 Delayed Quote.-11.32%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 0.62% 3723 End-of-day quote.-14.06%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on TAKEDA PHARMACEUTICAL COMP
07/12TAKEDA PHARMACEUTICAL : Provides Updates on Its Pharmacokinetic-guided Prophylax..
BU
07/08TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Opening of a Plasma Co..
BU
07/08TAKEDA PHARMACEUTICAL : and the New York Academy of Sciences Announce 2020 Innov..
BU
07/06TAKEDA PHARMACEUTICAL : eyes sale of OTC drug unit to focus on profitable produc..
AQ
06/30TAKEDA PHARMACEUTICAL : Announces Anticipated Financial Impact from Novartis Wit..
AQ
06/29TAKEDA PHARMACEUTICAL : Announces Pricing of its Unsecured U.S. Dollar-Denominat..
PU
06/28TAKEDA PHARMACEUTICAL : Japan's Takeda expects $200 million operating loss relat..
RE
06/28TAKEDA PHARMACEUTICAL : Announces Anticipated Financial Impact from Novartis' Wi..
PU
06/27TAKEDA PHARMACEUTICAL : Novartis pulls dry eye drug Xiidra's bid for approval in..
RE
06/25TAKEDA PHARMACEUTICAL : Announces the Publication of its Annual Report on Form 2..
AQ
More news
Financials
Sales 2021 3 271 B 30 587 M 30 587 M
Net income 2021 199 B 1 859 M 1 859 M
Net Debt 2021 3 763 B 35 190 M 35 190 M
P/E ratio 2021 56,1x
Yield 2021 4,83%
Capitalization 5 800 B 54 256 M 54 232 M
EV / Sales 2020
EV / Sales 2021 2,92x
Nbr of Employees 47 495
Free-Float 98,7%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMP
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 401,54 JPY
Last Close Price 3 723,00 JPY
Spread / Highest target 74,6%
Spread / Average Target 45,1%
Spread / Lowest Target 10,1%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Yasuhiko Yamanaka Director
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-14.06%53 751
JOHNSON & JOHNSON1.41%389 709
ROCHE HOLDING AG5.59%300 114
MERCK & CO., INC.-13.96%197 511
PFIZER, INC.-10.08%195 697
NOVARTIS AG-11.32%191 193